Would-be licensers lucky enough to hold the rights to products with compelling clinical data have always more or less been able to write their own checks in negotiating with Big Pharma, but never more so than now: 2006 saw an order of magnitude jump in up-front payments in late clinical licensing deals over previous years (See Figure 1).
Since 2002, the total paid by Big Pharma annually in licensing fees averaged around $600 million until 2006, when it...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?